MEI Pharma's 15min chart shows MACD Death Cross and Bollinger Bands Narrowing.

MEI Pharma's 15-minute chart has triggered a MACD Death Cross and Bollinger Bands Narrowing at 08/13/2025 14:15, indicating that the stock price has the potential to continue declining, with a decrease in the magnitude of stock price fluctuations.

MEI Pharma's 15-minute chart has triggered a MACD Death Cross and Bollinger Bands Narrowing at 08/13/2025 14:15, indicating that the stock price has the potential to continue declining, with a decrease in the magnitude of stock price fluctuations [1]. The MACD Death Cross, a technical indicator, occurs when the MACD line crosses below the signal line, often signaling a shift in momentum towards the downside. The narrowing Bollinger Bands, which measure volatility, suggest that the magnitude of price fluctuations is decreasing, which can be a precursor to further price declines.

Analysts have observed similar patterns in other stocks, including Alpha Cognition, where the narrowing Bollinger Bands and MACD Death Cross formations have led to further price decreases [2]. While these technical indicators provide valuable insights, it is crucial for investors to consider them in conjunction with fundamental analysis and broader market conditions.

In addition to the technical indicators, several analyst ratings and price targets have been updated recently, providing valuable insights into the potential performance of various stocks. As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts [1].

Positive Outlook: - Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1]. - Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1]. - CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1]. - Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1]. - Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1]. - Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1]. - Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1]. - Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1]. - JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1]. - Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1]. - Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1]. - MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1]. - Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1]. - Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1]. - Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1]. - Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1]. - Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1]. - Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1]. - Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1]. - Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1]. - PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1]. - Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1]. Neutral Outlook: - Allegiant Travel (ALGT) was initiated with a Neutral rating by UBS Group, with a price target lowered from $60.00 to $59.00 [1]. - Alaska Air Group (ALK) was initiated with a Neutral rating and a $49.00 price target by UBS Group [1]. - AvalonBay (AVB) was rated "Hold" by Evercore ISI with a price target of $229.00 [1]. - Benitec Biopharma (BNTC) was initiated with a "Buy" rating by TD Cowen [1]. - Broadridge Financial Solutions (BR) received a "Hold" rating from D.A. Davidson with a $220.00 target [1]. - Camden Property (CPT) was rated "Hold" by Evercore ISI with a price target of $124.00, implying a 13.26% upside [1]. - Citigroup (C) had a price target of $77.00 set by Evercore ISI, while Oppenheimer reiterated an "Outperform" rating [1]. - Coinbase Global (COIN) received a "Hold" rating from Goldman Sachs with a $268.00 price target [1]. - Coterra Energy (CTRA) was assigned a "Buy" rating by Barclays Capital with a $37.00 target [1]. - Crexendo (CXDO) was rated "Buy" at Northland Securities with a price target of $8.00 [1]. - Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1]. - DoubleVerify (DV) had its "Buy" rating reiterated by Craig Hallum [1]. - Emerson Electric Company (EMR) was rated "Buy" by TD Cowen, with a price target of $150.00 [1]. - Enovix (ENVX) received a "Buy" rating from Northland Securities with a $25.00 target [1]. - Enterprise Products Partners (EPD) was initiated with a "Hold" rating and a $33.00 price target by TD Cowen [1]. - Equity Residential (EQR) was upgraded by Evercore ISI from In-Line to Outperform, with a new target of $75.00, up from $74.00 [1]. - EQT Corp. (EQT) was initiated with an Overweight rating and a $65.00 target by Barclays [1]. - Essex Property (ESS) was rated "Hold" by Evercore ISI with a price target of $296.00 [1]. - Essent Group (ESNT) was downgraded from Outperform to Market Perform by Keefe, Bruyette & Woods, with a price target of $25.00 [1].

References:
[1] https://www.ainvest.com/news/alpha-cognition-chart-displays-bollinger-bands-narrowing-kdj-death-cross-bearish-marubozu-2508/
[2] https://www.ainvest.com/news/litecoin-surges-24-mei-pharma-boosts-treasury-100m-investment-2508/